TFP
VERV

Tilia Fiduciary Partners’s Verve Therapeutics VERV Stock Holding History

Tilia Fiduciary Partners’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-14
Closed – – 531
2022
Q3 		$0 Buy
+14
New +$447 ﹤0.01% 539

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Tilia Fiduciary Partners's VERV Position: Q4 2022 in Review

Tilia Fiduciary Partners sold out of Verve Therapeutics (VERV) in Q4 2022, closing a stake of 14 shares.

Tilia Fiduciary Partners first reported a position in VERV in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 123 funds tracked by Wall St. Rank hold VERV as of Q4 2022.

  • Tilia Fiduciary Partners reported no remaining Verve Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Tilia Fiduciary Partners sold 14 Verve Therapeutics shares in Q4 2022.
  • Tilia Fiduciary Partners first reported a position in Verve Therapeutics in Q3 2022 and held it in 1 quarter.
  • Tilia Fiduciary Partners's Verve Therapeutics position peaked at $0 in Q3 2022.
  • 123 funds tracked by Wall St. Rank held Verve Therapeutics as of Q4 2022.

Based on Tilia Fiduciary Partners's 13F filing for Q4 2022, filed 10 Feb 2023.